Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

Similar articles for PubMed (Select 21814200)

1.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

2.

The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.

Pastori C, Kapranov P, Penas C, Peschansky V, Volmar CH, Sarkaria JN, Bregy A, Komotar R, St Laurent G, Ayad NG, Wahlestedt C.

Proc Natl Acad Sci U S A. 2015 Jun 25. pii: 201424220. [Epub ahead of print]

PMID:
26111795
3.

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Kon Kim T, Gore SD, Zeidan AM.

Semin Hematol. 2015 Jul;52(3):172-83. doi: 10.1053/j.seminhematol.2015.04.003. Epub 2015 Apr 8. Review.

PMID:
26111464
4.

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Kandela I, Jin HY, Owen K; Reproducibility Project: Cancer Biology; Reproducibility Project Cancer Biology.

Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072.

5.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Jun 9. doi: 10.1038/leu.2015.138. [Epub ahead of print]

PMID:
26055303
6.

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM.

Chem Biol. 2015 Jun 18;22(6):755-63. doi: 10.1016/j.chembiol.2015.05.009. Epub 2015 Jun 4.

PMID:
26051217
7.

Phthalimide-Conjugated Ligands Promote Selective Protein Destabilization.

[No authors listed]

Cancer Discov. 2015 Jun 4. [Epub ahead of print]

PMID:
26045013
8.

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.

Zengerle M, Chan KH, Ciulli A.

ACS Chem Biol. 2015 Jun 16. [Epub ahead of print]

PMID:
26035625
9.

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE.

Science. 2015 Jun 19;348(6241):1376-81. doi: 10.1126/science.aab1433. Epub 2015 May 21.

PMID:
25999370
10.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.

Oncotarget. 2015 May 14. [Epub ahead of print]

11.

BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.

Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR.

Mol Cell. 2015 Jun 18;58(6):1028-39. doi: 10.1016/j.molcel.2015.04.011. Epub 2015 May 14.

PMID:
25982114
12.

Direct and indirect targeting of MYC to treat acute myeloid leukemia.

Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC.

Cancer Chemother Pharmacol. 2015 Jul;76(1):35-46. doi: 10.1007/s00280-015-2766-z. Epub 2015 May 9.

PMID:
25956709
13.

A Genetically Encoded FRET Probe to Detect Intranucleosomal Histone H3K9 or H3K14 Acetylation Using BRD4, a BET Family Member.

Nakaoka S, Sasaki K, Ito A, Nakao Y, Yoshida M.

ACS Chem Biol. 2015 May 15. [Epub ahead of print]

PMID:
25946208
14.

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.

Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ, Walkley CR.

Sci Rep. 2015 May 6;5:10120. doi: 10.1038/srep10120.

15.

Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.

Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B Jr, Suen JY, Tackett AJ, Gao L.

Epigenetics. 2015 Jun 3;10(6):460-6. doi: 10.1080/15592294.2015.1034416. Epub 2015 May 5.

PMID:
25941994
16.

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug.

Wermke M, Camgoz A, Paszkowski-Rogacz M, Thieme S, von Bonin M, Dahl A, Platzbecker U, Theis M, Ehninger G, Brenner S, Bornhäuser M, Buchholz F.

Blood. 2015 Jun 11;125(24):3760-8. doi: 10.1182/blood-2014-07-590646. Epub 2015 Apr 30.

PMID:
25931586
17.

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).

Jiang X, Lim CZ, Li Z, Lee PL, Yatim SM, Guan P, Li J, Zhou J, Pan J, Chng WJ, Chai CL, Yu Q.

PLoS One. 2015 Apr 30;10(4):e0122983. doi: 10.1371/journal.pone.0122983. eCollection 2015.

18.

Correction: Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells.

Fowler T, Ghatak P, Price DH, Conaway R, Conaway J, Chiang CM, Bradner JE, Shilatifard A, Roy AL.

PLoS One. 2015 Apr 22;10(4):e0126328. doi: 10.1371/journal.pone.0126328. eCollection 2015. No abstract available.

19.

Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.

Reikvam H, Hoang TT, Bruserud Ø.

Expert Rev Hematol. 2015 Jun;8(3):315-27. doi: 10.1586/17474086.2015.1036025. Epub 2015 Apr 22.

PMID:
25901742
20.

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ.

Oncogene. 2015 Apr 20. doi: 10.1038/onc.2015.92. [Epub ahead of print]

PMID:
25893291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk